Login to Your Account



GW Sets Terms for U.S. IPO; $40M for Cannabinoid Drugs

By Jennifer Boggs
Managing Editor

Wednesday, April 24, 2013
UK-based GW Pharmaceuticals plc set the terms for its proposed U.S. initial public offering (IPO), which would provide a listing on Nasdaq and nearly double its cash position ahead of the anticipated launch of lead cannabinoid product Sativex in the U.S.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription